Home » Stocks » CTSO

CytoSorbents Corporation (CTSO)

Stock Price: $8.16 USD -0.04 (-0.49%)
Updated May 13, 2021 2:19 PM EDT - Market open
Market Cap 348.29M
Revenue (ttm) 42.90M
Net Income (ttm) -8.55M
Shares Out 43.24M
EPS (ttm) -0.21
PE Ratio n/a
Forward PE 31.85
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $8.16
Previous Close $8.20
Change ($) -0.04
Change (%) -0.49%
Day's Open 8.27
Day's Range 8.06 - 8.27
Day's Volume 144,911
52-Week Range 7.13 - 11.74

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

The U.S Army Medical Research and Development Command has awarded CytoSorbents Corporation (NASDAQ: CTSO), a Defense Health Agency (DHA) Sequential Phase II Small Business Innovation Research (SBIR) con...

1 day ago - Benzinga

MONMOUTH JUNCTION, N.J., May 11, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader commercializing its CytoSorb® and other blood purification technologies to treat dea...

2 days ago - PRNewsWire

MONMOUTH JUNCTION, N.J., May 4, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader using its CytoSorb® blood purification technology to treat life-threatening condition...

1 week ago - PRNewsWire

MONMOUTH JUNCTION, N.J., April 27, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat...

2 weeks ago - PRNewsWire

The FDA has signed off conditional approval for the STAR-T study to assess CytoSorbents Corporation's (NASDAQ: CTSO) blood purification device, CytoSorb, to remove Ticagrelor. The company can now initia...

3 weeks ago - Benzinga

MONMOUTH JUNCTION, N.J., April 19, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care leader whose flagship E.U.

3 weeks ago - PRNewsWire

MONMOUTH JUNCTION, N.J., March 29, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb ® blood purification technology to trea...

1 month ago - PRNewsWire

MONMOUTH JUNCTION, N.J., March 16, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) announces the filing of an Investigational Device Exemption (IDE) application to conduct the clinical stud...

1 month ago - PRNewsWire

MONMOUTH JUNCTION, N.J., March 12, 2021 /PRNewswire/ --  CytoSorbents Corporation  (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to tre...

2 months ago - PRNewsWire

Shares of CytoSorbents (NASDAQ:CTSO) moved higher in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share were up 91.67% year over year to ($0.01), which beat...

2 months ago - Benzinga

MONMOUTH JUNCTION, N.J., March 9, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat ...

2 months ago - PRNewsWire

MONMOUTH JUNCTION, N.J., March 1, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its blood purification technology to treat deadly inf...

2 months ago - PRNewsWire

MONMOUTH JUNCTION, N.J., Feb. 24, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat ...

2 months ago - PRNewsWire

MONMOUTH JUNCTION, N.J., Feb. 18, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat ...

2 months ago - PRNewsWire

MONMOUTH JUNCTION, N.J., Feb. 16, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat ...

2 months ago - PRNewsWire

MONMOUTH JUNCTION, N.J., Feb. 4, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat d...

3 months ago - PRNewsWire

MONMOUTH JUNCTION, N.J., Jan. 21, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat ...

3 months ago - PRNewsWire

MONMOUTH JUNCTION, N.J., Jan. 19, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat ...

3 months ago - PRNewsWire

MONMOUTH JUNCTION, N.J., Jan. 11, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat ...

4 months ago - PRNewsWire

MONMOUTH JUNCTION, N.J., Jan. 4, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat d...

4 months ago - PRNewsWire

MONMOUTH JUNCTION, N.J., Dec. 17, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat ...

4 months ago - PRNewsWire

MONMOUTH JUNCTION, N.J., Dec. 9, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat d...

5 months ago - PRNewsWire

MONMOUTH JUNCTION, N.J., Dec. 2, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader that is commercializing its CytoSorb® blood purification technology to...

5 months ago - PRNewsWire

MONMOUTH JUNCTION, N.J., Nov. 25, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat ...

5 months ago - PRNewsWire

MONMOUTH JUNCTION, N.J., Nov. 23, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat ...

5 months ago - PRNewsWire

MONMOUTH JUNCTION, N.J., Nov. 12, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat ...

6 months ago - PRNewsWire

Cytosorbents Corporation (CTSO) CEO Phillip Chan on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

MONMOUTH JUNCTION, N.J., Nov. 4, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly infl...

6 months ago - PRNewsWire

MONMOUTH JUNCTION, N.J., Oct. 21, 2020 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly i...

6 months ago - PRNewsWire

MONMOUTH JUNCTION, N.J., Oct. 9, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader specializing in blood purification, announced today that the U.S. Army...

7 months ago - PRNewsWire

MONMOUTH JUNCTION, N.J., Sept. 21, 2020 /PRNewswire/ -- CytoSorbents Corporation (Nasdaq: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat...

7 months ago - PRNewsWire

MONMOUTH JUNCTION, N.J., Sept. 8, 2020 /PRNewswire/ -- CytoSorbents Corporation (Nasdaq: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat ...

8 months ago - PRNewsWire

MONMOUTH JUNCTION, N.J., Aug. 17, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) has entered into separate agreements with InvoSurg Inc.

8 months ago - PRNewsWire

Cytosorbents Corporation (CTSO) CEO Phillip Chan on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Shares of CytoSorbents (NASDAQ:CTSO) fell 2.15% in after-market trading after the company reported Q2 results.

9 months ago - Benzinga

MONMOUTH JUNCTION, N.J., Aug. 4, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly infl...

9 months ago - PRNewsWire

CytoSorbents (NASDAQ: CTSO) releases its next round of earnings this Tuesday, August 04.

9 months ago - Benzinga

MONMOUTH JUNCTION, N.J., Aug. 3, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly infl...

9 months ago - PRNewsWire

MONMOUTH JUNCTION, N.J., July 31, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader specializing in blood purification, announced today that the Assistan...

9 months ago - PRNewsWire

MONMOUTH JUNCTION, N.J., July 28, 2020 /PRNewswire/ -- CytoSorbents Corporation (Nasdaq: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat ...

9 months ago - PRNewsWire

MONMOUTH JUNCTION, N.J., July 28, 2020 /PRNewswire/ -- CytoSorbents Corporation (CTSO), CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purifica...

9 months ago - PRNewsWire

The company has priced its recently announced stock offering.

9 months ago - The Motley Fool

MONMOUTH JUNCTION, N.J., July 22, 2020 /PRNewswire/ -- CytoSorbents Corporation (Nasdaq: CTSO) (the "Company"), a critical care immunotherapy leader commercializing its CytoSorb® blood purification tech...

9 months ago - PRNewsWire

A stock offering overshadowed the company's impressive preliminary second-quarter results.

9 months ago - The Motley Fool

The S&P 500 closing up 0.8% at 2,251.84 and with the NASDAQ closing up 2.5% at 10,767.09, many investors are wondering how stocks keep rising despite the major recession in the time of a COVID-19 pandemic.

Other stocks mentioned: ACAD, GNW, HIBB, IBM, LLNW, NBEV, QIWI ...
9 months ago - 24/7 Wall Street

MONMOUTH JUNCTION, N.J., July 20, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly infl...

9 months ago - PRNewsWire

MONMOUTH JUNCTION, N.J., July 20, 2020 /PRNewswire/ -- CytoSorbents Corporation (Nasdaq: CTSO) (the "Company") a critical care immunotherapy leader commercializing its CytoSorb® blood purification techn...

9 months ago - PRNewsWire

MONMOUTH JUNCTION, N.J., June 29, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly infl...

10 months ago - PRNewsWire

MONMOUTH JUNCTION, N.J., June 24, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly infl...

10 months ago - PRNewsWire

MONMOUTH JUNCTION, N.J., June 9, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy leader specializing in blood purification, announced today that it was awarded...

11 months ago - PRNewsWire

About CTSO

Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of post-operative complications of cardiopulmonary bypass surgery, and maintainin... [Read more...]

Industry
Medical Devices
Founded
1997
CEO
Phillip Chan
Employees
195
Stock Exchange
NASDAQ
Ticker Symbol
CTSO
Full Company Profile

Financial Performance

In 2020, CytoSorbents's revenue was $41.00 million, an increase of 64.35% compared to the previous year's $24.95 million. Losses were -$7.84 million, -59.32% less than in 2019.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for CytoSorbents stock is "Strong Buy." The 12-month stock price forecast is 14.88, which is an increase of 82.35% from the latest price.

Price Target
$14.88
(82.35% upside)
Analyst Consensus: Strong Buy